BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1044 related articles for article (PubMed ID: 32852721)

  • 1. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
    Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
    PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
    Haroon S; Subramanian A; Cooper J; Anand A; Gokhale K; Byne N; Dhalla S; Acosta-Mena D; Taverner T; Okoth K; Wang J; Chandan JS; Sainsbury C; Zemedikun DT; Thomas GN; Parekh D; Marshall T; Sapey E; Adderley NJ; Nirantharakumar K
    BMC Infect Dis; 2021 Mar; 21(1):262. PubMed ID: 33722197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
    Choksi TT; Zhang H; Chen T; Malhotra N
    Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
    de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
    BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
    Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
    Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank.
    Safizadeh F; Nguyen TNM; Brenner H; Schöttker B
    Br J Clin Pharmacol; 2022 Jun; 88(6):2830-2842. PubMed ID: 34935181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension.
    Graham DJ; Izurieta HS; Muthuri SG; Zhang D; Sandhu AT; Lu Y; Zhao Y; Feng Y; Eworuke E; Lyu H; Gandotra C; Smith ER; Avagyan A; Wernecke M; Kelman JA; Forshee RA; MaCurdy TE
    J Gen Intern Med; 2021 Dec; 36(12):3802-3809. PubMed ID: 34599472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
    Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
    J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
    Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
    Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
    Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
    Bezabih YM; Bezabih A; Alamneh E; Peterson GM; Bezabhe W
    BMC Infect Dis; 2021 Jun; 21(1):527. PubMed ID: 34090358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
    An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
    J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
    Liu X; Liu Y; Chen K; Yan S; Bai X; Li J; Liu D
    J Med Virol; 2021 Feb; 93(2):854-862. PubMed ID: 32687223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.